A detailed history of Golden State Equity Partners transactions in Eli Lilly & CO stock. As of the latest transaction made, Golden State Equity Partners holds 95 shares of LLY stock, worth $75,588. This represents 0.05% of its overall portfolio holdings.

Number of Shares
95
Previous 2,279 95.83%
Holding current value
$75,588
Previous $2.02 Million 95.84%
% of portfolio
0.05%
Previous 0.46%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$772.14 - $960.02 $1.69 Million - $2.1 Million
-2,184 Reduced 95.83%
95 $84,000
Q3 2024

Oct 25, 2024

SELL
$772.14 - $960.02 $44,011 - $54,721
-57 Reduced 2.44%
2,279 $2.02 Million
Q2 2024

Jul 29, 2024

SELL
$724.87 - $909.04 $105,106 - $131,810
-145 Reduced 5.84%
2,336 $2.11 Million
Q4 2023

Feb 02, 2024

BUY
$525.19 - $619.13 $142,326 - $167,784
271 Added 12.26%
2,481 $1.45 Million
Q3 2023

Oct 20, 2023

SELL
$434.7 - $599.3 $41,731 - $57,532
-96 Reduced 4.16%
2,210 $1.19 Million
Q2 2023

Jul 19, 2023

BUY
$350.74 - $468.98 $6,313 - $8,441
18 Added 0.79%
2,306 $1.08 Million
Q1 2023

Jun 01, 2023

BUY
$310.63 - $364.82 $300,068 - $352,416
966 Added 73.07%
2,288 $786 Million
Q1 2022

May 18, 2022

SELL
$234.69 - $291.66 $122,508 - $152,246
-522 Reduced 28.31%
1,322 $379,000
Q1 2022

May 16, 2022

BUY
$234.69 - $291.66 $122,508 - $152,246
522 Added 39.49%
1,844 $344,000
Q4 2021

Feb 11, 2022

SELL
$224.85 - $279.04 $1,798 - $2,232
-8 Reduced 0.6%
1,322 $365,000
Q3 2021

Nov 15, 2021

SELL
$221.6 - $272.71 $15,068 - $18,544
-68 Reduced 4.86%
1,330 $307,000
Q2 2021

Aug 12, 2021

SELL
$180.55 - $233.54 $80,525 - $104,158
-446 Reduced 24.19%
1,398 $321,000
Q1 2021

May 13, 2021

BUY
$164.32 - $212.72 $79,859 - $103,381
486 Added 35.79%
1,844 $344,000
Q4 2020

Feb 08, 2021

BUY
$130.46 - $172.63 $177,164 - $234,431
1,358 New
1,358 $229,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Golden State Equity Partners Portfolio

Follow Golden State Equity Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

News

Stay updated on Golden State Equity Partners with notifications on news.